Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Sharp HealthCare
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients, more than 18 years of age incontinent with liquid to semi-formed stool.
- Non-ambulatory, hospitalized patients.
- History of passage of at least 1 stool in 24 hours.
Exclusion Criteria:
- Patients with suspected or confirmed rectal mucosal impairment or pathology.
- Patients with have undergone descending colon or rectal surgery within the preceding six months.
- Patients with significant hemorrhoids, growth, fissure, stricture, stenosis or local pathology (either benign and malignant) as observed during rectal examination.
- Patients suspected to have impacted stool or is suffering from constipation.
- Patients with confirmed pregnancy or suspected to be pregnant.
- Patients that have planned MRI examination over the duration of the study.
- Patients who have suffered recent cardiac arrest within the preceding 3 months.
- Patients enrolled in another clinical study or clinical trial.
- Patients on oral or IV anti-coagulation (e.g., IV heparin drip, acetylsalicylic acid , Plavix). Subcutaneous heparin or low molecular weight heparin are acceptable).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual confirmation that fecal material is diverted into the external collection bag through the device.
Time Frame: 120 +/- 8 hours
|
Yes or No response to visual observation of stool being collected through the transit sheath and collection bag.
|
120 +/- 8 hours
|
|
Visual confirmation of no soiling, leaking or seepage of fecal secretions from the periphery of the device.
Time Frame: 120 +/- 8 hours
|
Yes or No response to visual observation of soiling, leaking or seepage around periphery of device.
|
120 +/- 8 hours
|
|
Number of hours for which the device stays on without change or removal.
Time Frame: 120 +/- 8 hours
|
Quantitative measure of duration of device use.
The cause of the change or removal will be documented.
|
120 +/- 8 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual confirmation of no active bleeding on the external periphery of the device (transit sheath or collection bag) over the usage of the device.
Time Frame: 120 +/- 8 hours
|
Yes or No response from visual observation of any bleeding on the external periphery of the device.
|
120 +/- 8 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CON/2013/FI003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fecal Incontinence
-
NCT07436676RecruitingFecal Incontinence (FI)
-
NCT04472923CompletedFecal Incontinence in Children
-
NCT07192328CompletedHealthy Female Volunteer | Fecal Incontinence (FI)
-
NCT06053879CompletedFecal Incontinence in Children
-
NCT05222217CompletedGas Incontinence | Soilings, Fecal
-
NCT01421823Withdrawn
-
NCT05040139CompletedConstipation Aggravated | Fecal Incontinence With Fecal Urgency
-
NCT07239076Recruiting
-
NCT02349334CompletedBowel Incontinence | Faecal Incontinence
Clinical Trials on Consure 120 Stool Management System
-
NCT05904301RecruitingRheumatoid Arthritis | Celiac Disease | Giant Cell Arteritis | Sjogren's Syndrome | Takayasu Arteritis | Primary Antiphospholipid Syndrome | Behcet Disease | Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis | Hereditary and Acquired Angioedema
-
NCT00364585CompletedBenign Prostatic Hyperplasia
-
NCT02905825CompletedHelicobacter Pylori Infection
-
NCT06231849Not yet recruitingOpioid Use Disorder | Opioid Dependence | Opioid Use
-
NCT04545151CompletedDiabetes Mellitus, Type 1
-
NCT06159244RecruitingCorticosteroids | Intestinal Microbiota | Alcohol | Severe Acute Alcoholic Hepatitis
-
NCT04103840UnknownSevere Alcoholic Hepatitis | Chronic Liver Disease and Cirrhosis
-
NCT07338890Not yet recruitingPopliteal Artery Stenosis | Superficial Femoral Artery Stenosis | Iliac Artery Stenosis
-
NCT05276557RecruitingEfficacy | Safety | Helicobacter Pylori